Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 2
2006 3
2008 1
2009 1
2010 1
2011 2
2012 2
2013 3
2014 2
2015 1
2016 2
2017 2
2018 2
2019 4
2020 3
2021 1
2022 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Results by year

Filters applied: . Clear all
Page 1
The Effect of Vaccination against COVID-19 in Cancer Patients: Final Results of the COICA Trial.
Di Lorenzo G, Ingenito C, D'Ambrosio B, Ranieri C, Iuliucci MR, Iervolino M, Primiano F, Buonerba L, Busto G, Ferrara C, Libroia A, Ragone G, De Falco F, Costabile F, Fimiani P, Ugliano F, Leo E, Roviello G, Scafuri L, Buonerba C. Di Lorenzo G, et al. Among authors: ferrara c. Oncology. 2022;100(9):512-518. doi: 10.1159/000525962. Epub 2022 Jul 11. Oncology. 2022. PMID: 35817009 Free article.
The Impact of Routine Molecular Screening for SARS-CoV-2 in Patients Receiving Anticancer Therapy: An Interim Analysis of the Observational COICA Study.
Di Lorenzo G, Iervolino M, Primiano F, D'Ambrosio M, Ingenito C, Buonerba L, Busto G, Ferrara C, Libroia A, Ragone G, De Falco F, Costabile F, Fimiani P, Ugliano F, Ranieri C, Leo E, Roviello G, Scafuri L, Guerra G, Buonerba C. Di Lorenzo G, et al. Among authors: ferrara c. Oncology. 2022;100(9):505-511. doi: 10.1159/000521086. Epub 2021 Nov 26. Oncology. 2022. PMID: 34839299 Free article.
COVID 19 therapies and anti-cancer drugs: A systematic review of recent literature.
Di Lorenzo G, Di Trolio R, Kozlakidis Z, Busto G, Ingenito C, Buonerba L, Ferrara C, Libroia A, Ragone G, Ioio CD, Savastano B, Polverino M, De Falco F, Iaccarino S, Leo E. Di Lorenzo G, et al. Among authors: ferrara c. Crit Rev Oncol Hematol. 2020 Aug;152:102991. doi: 10.1016/j.critrevonc.2020.102991. Epub 2020 May 21. Crit Rev Oncol Hematol. 2020. PMID: 32544802 Free PMC article.
Coronavirus Disease 2019 Emergency and Cancer in the South of Italy: What's New for the Oncologist?
Ingenito C, Buonerba L, Ferrara C, Busto G, Libroia A, Ragone G, Leo E, Savastano B, Ioio CD, De Falco F, Iaccarino S, Tarantino L, Polverino M, Di Lorenzo G. Ingenito C, et al. Among authors: ferrara c. Front Med (Lausanne). 2020 May 6;7:189. doi: 10.3389/fmed.2020.00189. eCollection 2020. Front Med (Lausanne). 2020. PMID: 32435648 Free PMC article. No abstract available.
The PET-Tracer 89Zr-Df-IAB22M2C Enables Monitoring of Intratumoral CD8 T-cell Infiltrates in Tumor-Bearing Humanized Mice after T-cell Bispecific Antibody Treatment.
Griessinger CM, Olafsen T, Mascioni A, Jiang ZK, Zamilpa C, Jia F, Torgov M, Romero JM, Marchioni F, Satpayev D, Lee C, Zhang G, Nayak TK, Pincha M, Amann M, Mohan PLB, Richard M, Nicolini VG, Sam J, Claus C, Ferrara C, Brünker P, Bacac M, Umana P, Rüttinger D, Wilson IA, Gudas J, Klein C, Tessier JJL. Griessinger CM, et al. Among authors: ferrara c. Cancer Res. 2020 Jul 1;80(13):2903-2913. doi: 10.1158/0008-5472.CAN-19-3269. Epub 2020 May 14. Cancer Res. 2020. PMID: 32409308
Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy.
Claus C, Ferrara C, Xu W, Sam J, Lang S, Uhlenbrock F, Albrecht R, Herter S, Schlenker R, Hüsser T, Diggelmann S, Challier J, Mössner E, Hosse RJ, Hofer T, Brünker P, Joseph C, Benz J, Ringler P, Stahlberg H, Lauer M, Perro M, Chen S, Küttel C, Bhavani Mohan PL, Nicolini V, Birk MC, Ongaro A, Prince C, Gianotti R, Dugan G, Whitlow CT, Solingapuram Sai KK, Caudell DL, Burgos-Rodriguez AG, Cline JM, Hettich M, Ceppi M, Giusti AM, Crameri F, Driessen W, Morcos PN, Freimoser-Grundschober A, Levitsky V, Amann M, Grau-Richards S, von Hirschheydt T, Tournaviti S, Mølhøj M, Fauti T, Heinzelmann-Schwarz V, Teichgräber V, Colombetti S, Bacac M, Zippelius A, Klein C, Umaña P. Claus C, et al. Among authors: ferrara c. Sci Transl Med. 2019 Jun 12;11(496):eaav5989. doi: 10.1126/scitranslmed.aav5989. Sci Transl Med. 2019. PMID: 31189721 Free PMC article.
The homozygous K280N troponin T mutation alters cross-bridge kinetics and energetics in human HCM.
Piroddi N, Witjas-Paalberends ER, Ferrara C, Ferrantini C, Vitale G, Scellini B, Wijnker PJM, Sequiera V, Dooijes D, Dos Remedios C, Schlossarek S, Leung MC, Messer A, Ward DG, Biggeri A, Tesi C, Carrier L, Redwood CS, Marston SB, van der Velden J, Poggesi C. Piroddi N, et al. Among authors: ferrara c. J Gen Physiol. 2019 Jan 7;151(1):18-29. doi: 10.1085/jgp.201812160. Epub 2018 Dec 21. J Gen Physiol. 2019. PMID: 30578328 Free PMC article.
GA101 P329GLALA, a variant of obinutuzumab with abolished ADCC, ADCP and CDC function but retained cell death induction, is as efficient as rituximab in B-cell depletion and antitumor activity.
Herter S, Herting F, Muth G, van Puijenbroek E, Schlothauer T, Ferrara C, Brady K, Lang S, Bacac M, Mössner E, Umana P, Klein C. Herter S, et al. Among authors: ferrara c. Haematologica. 2018 Feb;103(2):e78-e81. doi: 10.3324/haematol.2017.178996. Epub 2017 Oct 27. Haematologica. 2018. PMID: 29079598 Free PMC article. No abstract available.
27 results